BeStock  

Labcorp Holdings LH

US equityMarket cap rank #664Diagnostics & ResearchInfectious DiseaseCRO
$367.13 −$1.75 (-0.47%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $367.13 0.00%
Open$371.48
Prev close$368.88
Day range$366.33 – $372.50
Volume890.6K
Market cap$29.81B
P/E (TTM)30.1
Dividend yield0.78%

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership100.6%-0.39 pts vs. prior quarter
Institutions holding1,312-2 vs. prior quarter
Insider trades (recent)18 buys / 32 sellsNet selling
Short interest3.13% of floatDays to cover 3.0 · as of 30 Oct 2026
Short-sale volume share24.3%5-day average of daily volume

Short-sale volume as % of daily volume

6%19%31%44%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$3.19M (12 inflow days, 8 outflow days).

Net flow by order size, last 20 sessions

−$3.8MSuper+$587.3KBig−$6.4MMid−$41.0MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 29.3% of shares outstanding.

Largest holders

  • BlackRock8.05%
  • Vanguard Capital Management, LLC7.10%
  • State Street Global Advisors4.86%
  • Victory Capital Management Inc.4.83%
  • Vanguard Portfolio Management, LLC4.46%
  • FMR4.24%
  • Boston Partners Global Investors, Inc.3.63%
  • Geode Capital Management, LLC2.69%

By investor type

  • Mutual Fund88.13%
  • Hedge Fund4.44%
  • Public Company3.57%
  • Government Pension Fund1.28%
  • Private Company1.25%
  • Sovereign Wealth Fund1.04%
  • Individual/Insider0.38%
  • Family Office/Trust0.35%

Reported short interest has risen from 2.39% to 3.13% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
FMR Mutual Fund 2026/Q4 +1,611,797 4.2%
Goldman Sachs Asset Management, L.P. Mutual Fund 2026/Q4 +555,186 1.1%
Deka Investment GmbH Mutual Fund 2026/Q4 +284,595 0.6%
Citadel Advisors LLC Hedge Fund 2026/Q4 +230,053 0.3%
D. E. Shaw & Co., L.P. Hedge Fund 2026/Q4 +202,062 0.3%
Invesco Ltd. Mutual Fund 2026/Q4 +199,457 0.7%
Putnam LLC Mutual Fund 2026/Q4 +187,478 0.2%
Strategic Advisers LLC Mutual Fund 2026/Q4 +172,885 0.3%
Gilder Gagnon Howe & Co. LLC Mutual Fund 2026/Q4 +122,278 0.2%
Aquatic Capital Management LLC Hedge Fund 2026/Q4 +107,950 0.1%
Invesco Capital Management LLC Mutual Fund 2026/Q4 +100,907 1.2%
Boone Capital Management LLC Hedge Fund 2026/Q4 +87,551 0.1%
Qube Research & Technologies Ltd Mutual Fund 2026/Q4 +83,376 0.2%
JPMorgan Chase & Co. Public Company 2026/Q4 +77,321 0.4%
Holocene Advisors, LP Hedge Fund 2026/Q4 +74,856 0.1%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
9 Nov 2026 Brian Caveney Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer Open Market Disposition -2,000 $372.04 34,562
3 Nov 2026 Megan Bailey Former Executive VP and President of Central Laboratory Services & International Labcorp Intent to Sell (Form 144) -3,035 $361.16 –
2 Nov 2026 Bryan Vaughn Executive VP & President of Diagnostics Automatic Disposition -306 $353.70 6,845
1 Nov 2026 Akinbolade Oyegunwa Executive VP and Chief Information & Technology Officer Derivative Exercise and Sale -118 $355.59 5,316
1 Nov 2026 Bryan Vaughn Executive VP & President of Diagnostics Derivative Exercise and Sale -194 $355.59 7,151
31 Oct 2026 Akinbolade Oyegunwa Executive VP and Chief Information & Technology Officer Derivative Exercise and Retained +252 – 5,316
31 Oct 2026 Bryan Vaughn Executive VP & President of Diagnostics Derivative Exercise and Retained +306 – 7,151
29 Oct 2026 Richelle Parham Independent Director Open Market Disposition -1,078 $361.22 2,288
31 Aug 2026 Brian Caveney Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer Other Derivative Acquisition +3,000 – 7,170
31 Aug 2026 Akinbolade Oyegunwa Executive VP and Chief Information & Technology Officer Other Derivative Acquisition +750 – 2,940
31 Aug 2026 Jonathan Meltzer Chief Operating Officer Other Derivative Acquisition +900 – 3,594
31 Aug 2026 Bryan Vaughn Executive VP & President of Diagnostics Other Derivative Acquisition +1,500 – 5,204
16 Aug 2026 Kerrii Anderson Independent Director Automatic Disposition -3,000 $318.02 6,851
10 Aug 2026 Adam Schechter Chairperson & CEO Automatic Disposition -4,669 $320.37 102,565
3 Aug 2026 Amy Summy Executive VP, Chief Marketing Officer & Consumer Health Lead Open Market Disposition -924 $306.74 6,956
2 Aug 2026 Peter Wilkinson Chief Accounting Officer Open Market Disposition -82 $309.22 1,770
2 Aug 2026 Peter Wilkinson Chief Accounting Officer Derivative Exercise and Sale -1,338 $309.23 1,770
1 Jul 2026 Kathryn Kyle Executive Vice President Intent to Sell (Form 144) -92 $286.19 –
1 Jul 2026 Bryan Vaughn Executive VP & President of Diagnostics Intent to Sell (Form 144) -234 $286.19 –
1 Jul 2026 Kathryn Kyle Executive Vice President Derivative Exercise and Sale -165 $286.19 3,904

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 2,544,414 3.1% 3.0
15 Oct 2026 2,557,656 3.2% 4.2
30 Sep 2026 2,684,363 3.3% 3.0
15 Sep 2026 2,448,617 3.0% 3.3
31 Aug 2026 2,103,302 2.6% 3.2
14 Aug 2026 1,938,163 2.4% 3.8

Discussion

No comments yet — be the first to weigh in on LH.

Sign in to join the discussion.

Scroll to Top